The best-known peptide-based radiotheranostic agents are the radiolabeled somatostatin analogue, 177Lu-Dotatate (Luthatera®), and PSMA ligand, 177Lu-PSMA-617 (Pluvicto®), for neuro-endocrine tumors and prostate cancer therapy, respectively (28, 29). This evidence concerns the gene FOLH1 and prostate carcinoma.